Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Imprime PGG · 1 trial · 1 indication
ORR by RECIST v1.1 following treatment with Imprime PGG + pembrolizumab
| Arm | Type | Description |
|---|---|---|
| Experimental | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Imprime PGG | BIOLOGICAL | Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle. |
| Pembrolizumab | BIOLOGICAL | Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion. |
Inclusion Criteria: 1. The patient (or legally acceptable representative if applicable) provides written informed consent for the trial. 2. Be 18 years of age on day of signing informed consent. 3. Have historically confirmed histological diagnosis of metastatic ER/PR+/HER2(-) subtype breast cancer...
Imprime PGG is an investigational monoclonal antibody being studied for the treatment of malignant neoplasm of breast, specifically in patients with HR+/HER2- metastatic breast cancer. It is being evaluated in combination with pembrolizumab in a Phase 2 clinical trial.
Imprime PGG is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this investigational therapy for oncology indications.
Imprime PGG is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients.
Imprime PGG is being studied in a Phase 2 clinical trial with the identifier NCT05159778. This trial, titled 'Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)', has been completed and enrolled 26 participants in the United States.
Yes, Imprime PGG is a monoclonal antibody. It is being investigated as a therapeutic agent in oncology, specifically for the treatment of malignant neoplasm of breast, and is currently in Phase 2 clinical development.